News
TAK
18.90
+0.21%
0.04
Weekly Report: what happened at TAK last week (0921-0925)?
Weekly Report · 18h ago
Innovent Expands Phase 3 IBI363 Study To Non-Squamous Lung Cancer; Stock Down
NASDAQ · 22h ago
Innovent Biologics announces expansion of global Phase 3 MarsLight-11 trial
TipRanks · 1d ago
This Cancer Drug Is Already Working. Now Its Nvidia-Backed Maker Is Going Public: Here’s What You Need to Know About Its IPO
Barchart · 1d ago
AC Immune: Buy Continued ACI-7104 Progress, PD, And Pipeline Expansions
Seeking Alpha · 4d ago
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026
Barchart · 6d ago
Nvidia-Backed AI Drug Discovery Company Iambic Therapeutics Files for Nasdaq IPO, to Use Proceeds for Cancer Drug Development
Benzinga · 09/22 02:00
Weekly Report: what happened at TAK last week (0914-0918)?
Weekly Report · 09/21 09:13
Takeda Unveils $22.2 Mln CSR Collaborations Focused On Climate-Resilient Health; Stock Up
NASDAQ · 09/21 05:39
5 Undervalued Oncology Stocks Wall Street Is Overlooking
Seeking Alpha · 09/18 13:22
Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems
Barchart · 09/18 00:00
Full Transcript: Takeda Pharmaceutical Co Q1 2026 Earnings Call
Benzinga · 09/17 13:06
Takeda Pharmaceutical Company (TAK) Gets a Buy from Bank of America Securities
TipRanks · 09/14 15:35
Best Value Stocks to Buy for September 14th
NASDAQ · 09/14 10:03
Takeda's Zasocitinib NDA Gets FDA Priority Review For Plaque Psoriasis; PDUFA Date Set For Q1' 27
NASDAQ · 09/14 09:35
Best Income Stocks to Buy for September 14th
NASDAQ · 09/14 09:28
Takeda announces FDA acceptance of zasocitinib under priority review
TipRanks · 09/14 09:15
Weekly Report: what happened at TAK last week (0907-0911)?
Weekly Report · 09/14 09:13
Takeda's Zasocitinib Shows About 70% Of Patients Achieving Clear Or Almost Clear Skin At Week 16 In Phase 3 LATITUDE PsO Studies Of Nearly 3,000 Patients
Benzinga · 09/14 07:52
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
Barchart · 09/14 02:00
More
Webull provides a variety of real-time TAK stock news. You can receive the latest news about Takeda Pharm through multiple platforms. This information may help you make smarter investment decisions.
About TAK
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.